Article
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Oncotarget - 8 Dec 2015
Gray Elin S, Rizos Helen, Reid Anna L, Boyd Suzanah C, Pereira Michelle R, Lo Johnny, Tembe Varsha, Freeman James, Lee Jenny H J, Scolyer Richard A, Siew Kelvin, Lomma Chris, Cooper Adam, Khattak Muhammad A, Meniawy Tarek M, Long Georgina V, Carlino Matteo S, Millward Michael, Ziman Melanie
Abstract excerpt
Repeat tumor biopsies to study genomic changes during therapy are difficult, invasive and data are confounded by tumoral heterogeneity. The analysis of circulating tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and the genetic evolution of tumors in response to therapy. Mutation-specific droplet digital PCR was used to measure plasma concentrations of oncogenic BRAF and NRAS variants in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.